CD56 on immune and tumor cells: what is known and beyond?

IF 3.8 3区医学 Q3 IMMUNOLOGY

Clinical and experimental immunology Pub Date : 2025-01-21 DOI:10.1093/cei/uxaf056

Yuan Meng, Feng Zhang, Yiying Jin, Zhihao Wen, Fengyu Chen, Nenggang Jiang, Hongyan Liao

{"title":"CD56 on immune and tumor cells: what is known and beyond?","authors":"Yuan Meng, Feng Zhang, Yiying Jin, Zhihao Wen, Fengyu Chen, Nenggang Jiang, Hongyan Liao","doi":"10.1093/cei/uxaf056","DOIUrl":null,"url":null,"abstract":"<p><p>Recent studies on cancer cells and the immune microenvironment have offered valuable insights into personalized diagnostics, targeted therapies, and individualized prognosis evaluation. A comprehensive understanding of new and existing biomarkers in both healthy and diseased conditions is essential for advancing these goals. CD56, also known as the neural cell adhesion molecule, is a well-established phenotypic marker of natural killer cells. It is also expressed by various immune cells under healthy conditions, such as T cells, dendritic cells, and monocytes. Despite its widespread expression, the functions of CD56 are still poorly understood. In patients with infectious, autoimmune, or malignant diseases, changes in the proportion, phenotype, and function of CD56+ immune cells have been observed. In patients with hematolymphoid disorders, malignant cells may exhibit aberrant CD56 expression, making it a valuable diagnostic and prognostic marker. CD56 also holds potential as a therapeutic target. In this review, we summarize the current understanding of CD56 expression and function across various immune cells in infectious, immune-related, and cancerous conditions. We also explore its diagnostic, prognostic, and therapeutic significance in hematological malignancies. This review aims to present a comprehensive overview of CD56 in hematolymphoid disorders, offering insights into how CD56 and its associated immune cells could inform future immunotherapeutic strategies.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449139/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxaf056","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent studies on cancer cells and the immune microenvironment have offered valuable insights into personalized diagnostics, targeted therapies, and individualized prognosis evaluation. A comprehensive understanding of new and existing biomarkers in both healthy and diseased conditions is essential for advancing these goals. CD56, also known as the neural cell adhesion molecule, is a well-established phenotypic marker of natural killer cells. It is also expressed by various immune cells under healthy conditions, such as T cells, dendritic cells, and monocytes. Despite its widespread expression, the functions of CD56 are still poorly understood. In patients with infectious, autoimmune, or malignant diseases, changes in the proportion, phenotype, and function of CD56+ immune cells have been observed. In patients with hematolymphoid disorders, malignant cells may exhibit aberrant CD56 expression, making it a valuable diagnostic and prognostic marker. CD56 also holds potential as a therapeutic target. In this review, we summarize the current understanding of CD56 expression and function across various immune cells in infectious, immune-related, and cancerous conditions. We also explore its diagnostic, prognostic, and therapeutic significance in hematological malignancies. This review aims to present a comprehensive overview of CD56 in hematolymphoid disorders, offering insights into how CD56 and its associated immune cells could inform future immunotherapeutic strategies.

查看原文本刊更多论文

CD56对免疫和肿瘤细胞的作用：已知的和未知的是什么？

最近对癌细胞和免疫微环境的研究为个性化诊断、靶向治疗和个性化预后评估提供了有价值的见解。全面了解健康和疾病条件下新的和现有的生物标志物对于推进这些目标至关重要。CD56，也被称为神经细胞粘附分子（NCAM），是一种公认的自然杀伤细胞（NK）表型标志物。在健康条件下，它也由各种免疫细胞表达，如T细胞、树突状细胞和单核细胞。尽管CD56广泛表达，但人们对其功能仍知之甚少。在感染性、自身免疫性或恶性疾病患者中，已经观察到CD56+免疫细胞的比例、表型和功能的变化。在血淋巴疾病患者中，恶性细胞可能表现出异常的CD56表达，使其成为有价值的诊断和预后标志物。CD56也具有作为治疗靶点的潜力。在这篇综述中，我们总结了目前对CD56在感染、免疫相关和癌症疾病中各种免疫细胞中的表达和功能的了解。我们也探讨了它在血液系统恶性肿瘤中的诊断、预后和治疗意义。本综述旨在全面概述CD56在血淋巴疾病中的作用，并提供CD56及其相关免疫细胞如何为未来的免疫治疗策略提供信息的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental immunology 医学-免疫学

CiteScore

8.40

自引率

2.20%

发文量

101

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.